Citadel Advisors’s Tema Oncology ETF CANC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$813K Buy
+19,345
New +$818K ﹤0.01% 9015
2026
Q2
– Sell
-69,106
Closed -$2.54M – 13761
2026
Q1
$2.54M Buy
+69,106
New +$2.52M ﹤0.01% 5589

Other funds holding CANC

Citadel Advisors's CANC Position: Q3 2026 in Review

Citadel Advisors opened a new position in Tema Oncology ETF (CANC) in Q3 2026: 19,345 shares worth $813K. The stake represents ﹤0.01% of the portfolio and ranks #9015 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CANC as recently as Q1 2026.

Citadel Advisors first reported a position in CANC in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.54M in Q1 2026. 17 funds tracked by Wall St. Rank hold CANC as of Q3 2026.

  • Citadel Advisors held 19,345 shares of Tema Oncology ETF worth $813K as of Q3 2026.
  • Tema Oncology ETF was a new Citadel Advisors position in Q3 2026.
  • Tema Oncology ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #9015 holding.
  • Citadel Advisors first reported a position in Tema Oncology ETF in Q1 2026 and has held it in 2 quarters since.
  • Citadel Advisors's Tema Oncology ETF position peaked at $2.54M in Q1 2026.
  • 17 funds tracked by Wall St. Rank held Tema Oncology ETF as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.